Oral administration of 17β-estradiol over 3 months without progestin co-administration does not improve coronary flow reserve in post-menopausal women: A randomized placebo-controlled cross-over CMR study

Journal of Cardiovascular Magnetic Resonance

Volumn 9, Issue 4, 2007, Pages 665-672

  Schwitter, Juerg ^a   Kozerke, Sebastian ^b   Bremerich, Jens ^c   Baltes, Christof ^b   Jost, Christine Attenhofer ^a   Birkhäuser, Martin ^d   Boesiger, Peter ^b   Buser, Peter ^c  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b ETH ZURICH   (Switzerland)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d UNIVERSITY OF BERN   (Switzerland)

Author keywords

Cardiovascular Magnetic Resonance; Coronary Flow Reserve; Estrogen Replacement Therapy; Flow Measurements; Postmenopausal Women

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPYRIDAMOLE; ESTRADIOL; ESTROFEM; GESTAGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; CORONARY SINUS; CROSSOVER PROCEDURE; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HEART RATE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; NUCLEAR MAGNETIC RESONANCE; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; STRESS ECHOCARDIOGRAPHY; SYSTOLIC BLOOD PRESSURE; VASODILATATION; ANALYSIS OF VARIANCE; ESTROGEN THERAPY; METHODOLOGY; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; ORAL DRUG ADMINISTRATION; REPRODUCIBILITY; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; ANALYSIS OF VARIANCE; CORONARY CIRCULATION; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ECHOCARDIOGRAPHY, STRESS; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; PLACEBOS; POSTMENOPAUSE; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME;

EID: 34250749625     PISSN: 10976647     EISSN: 1532429X     Source Type: Journal    
DOI: 10.1080/10976640601138730     Document Type: Article

References (52)

1. Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Willett WC, Rosner B, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996;335:453-61. [erratum appears in N Engl J Med 1996;335:1406.
2. Psaty BM, Heckbert SR, Atkins D, Lemaitre R, Koepsell TD, Wahl PW, et al. The risk ofmyocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women. Arch Int Med 1994;154:1333-9.
3. Varas-Lorenzo C, Garcia-Rodriguez LA, Perez-Gutthann S, Duque-Oliart A. Hormone replacement therapy and incidence of acute myocardial infarction. A population-based nested case-control study. Circulation 2000;101:2572-8.
4. Grodstein F, Manson JE, Stampfer MJ. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Women's Health 2006;15:35-44.
5. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA 1995;273:199-208. [erratum appears in JAMA 1995; 6; 274:1676.
6. Soma MR, Osnago-Gadda I, Paoletti R, Fumagalli R, Morrisett JD, Meschia M, et al. The lowering of lipoprotein[a] induced by estrogen plus progesterone replacement therapy in postmenopausal women. Arch Int Med 1462;153:1462-8.
7. Subbiah MT, Kessel B, Agrawal M, Rajan R, Abplanalp W, Rymaszewski Z. Antioxidant potential of specific estrogens on lipid peroxidation. J Clin Endocrin & Metab 1993;77:1095-7.
8. Koh KK, Bui MN, Mincemoyer R,Cannon III RO. Effects of hormone therapy on inflammatory cell adhesion molecules in postmenopausal healthy women. Am J Cardiol 1997;80:1505-7.
9. Wakatsuki A, Okatani Y, Ikenoue N, Fukaya T. Effect of medroxyprogesterone acetate on vascular inflammatory markers in postmenopausal women receiving estrogen. Circulation 2002;105:1436-9.
10. Rajkumar C, Kingwell BA, Cameron JD, Waddell T, Mehra R, Christophidis N, et al. Hormonal therapy increases arterial compliance in postmenopausal women. J Am Coll Cardiol 1997;30:350-6.
11. Koh KK, Cardillo C, Bui MN, Hathaway L, Csako G, Waclawiw MA, et al. Vascular effects of estrogen and cholesterol-lowering therapies in hypercholesterolemic postmenopausal women. Circulation 1999;99:354-60.
12. Lieberman EH, Gerhard MD, Uehata A, Walsh BW, Selwyn AP, Ganz P, et al. Estrogen improves endothelium-dependent, flow-mediated vasodilation in postmenopausal women. Ann Int Med 1994;121:936-41.
13. Koh KK, Blum A, Hathaway L, Mincemoyer R, Csako G, Waclawiw MA, Panza JA, at al. Vascular effects of estrogen and vitamin E therapies in postmenopausal women. Circulation 1999;100:1851-7.
14. Gilligan DM, Badar DM, Panza JA, Quyyumi AA ,Cannon III RO. Acute vascular effects of estrogen in postmenopausal women. Circulation 1994;90:786-91.
15. Jiang C, Sarrel PM, Poole-Wilson PA, Collins P. Acute effect of 17 beta-estradiol on rabbit coronary artery contractile responses to endothelin-1. Am J Physiol 1992;263.
16. Reis SE, Gloth ST, Blumenthal RS, Resar JR, Zacur HA, Gerstenblith G, et al. Ethinyl estradiol acutely attenuates abnormal coronary vasomotor responses to acetylcholine in postmenopausal women. Circulation 1994;89:52-60.
17. Collins P, Rosano GM, Sarrel PM, Ulrich L, Adamopoulos S, Beale CM, et al. 17 beta-Estradiol attenuates acetylcholine-induced coronary arterial constriction in women but not men with coronary heart disease. Circulation 1995;92:24-30.
18. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002; 288: 49-57. [erratum appears in JAMA 2002;4;288:1064].
19. Herrington DM, Reboussin DM, Brosnihan KB, Sharp PC, Shumaker SA, Snyder TE, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000;343:522-9.
20. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
21. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, et al. Estrogen plus progestin and the risk of coronary heart disease.[see comment]. N Engl J Med 2003;349:523-34.
22. Hsia J, Langer RD, Manson JE, Kuller L, Johnson KC, Hendrix SL, et al. Conjugated Equine Estrogens and Coronary Heart Disease: The Women's Health Initiative. Arch Int Med 2006;166:357-65.
23. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-12.
24. Wakatsuki A, Okatani Y, Ikenoue N, Fukaya T. Effect of medroxyprogesterone acetate on endothelium-dependent vasodilation in postmenopausal women receiving estrogen. Circulation 2001;104:1773-8.
25. Kawano H, Motoyama T, Hirai N, Yoshimura T, Kugiyama K, Ogawa H, et al. Effect of medroxyprogesterone acetate plus estradiol on endothelium-dependent vasodilation in postmenopausal women. Am J Cardiol 2001;87:238-40.
26. Sorensen KE, Dorup I, Hermann AP ,Mosekilde L. Combined hormone replacement therapy does not protect women against the age-related decline in endothelium-dependent vasomotor function. Circulation 1998;97:1234-8.
27. Caine YG, Bauer KA, Barzegar S, ten Cate H, Sacks FM, Walsh BW, et al. Coagulation activation following estrogen administration to postmenopausal women. Thromb & Haemost 1992;68:392-5.
28. Mikkola TS, Clarkson TB. Estrogen replacement therapy, atherosclerosis, and vascular function. Cardiovasc Research 2002;53:605-19.
29. Losordo DW, Kearney M, Kim EA, Jekanowski J ,Isner JM. Variable expression of the estrogen receptor in normal and atherosclerotic coronary arteries of premenopausal women. Circulation 1994;89:1501-10.
30. van Rossum AC, Visser FC, Hofman MB, Galjee MA, Westerhof N, Valk J. Global left ventricular perfusion: noninvasive measurement with cine MR imaging and phase velocity mapping of coronary venous outflow. Radiology 1992;182:685-91.
31. Schwitter J, DeMarco T, Kneifel S, von Schulthess GK, Jorg MC, Arheden H, et al. Magnetic resonance-based assessment of global coronary flow and flow reserve and its relation to left ventricular functional parameters: a comparison with positron emission tomography. Circulation 2000;101:2696-702.
32. Lund GK, Wendland MF, Shimakawa A, Arheden H, Stahlberg F, Higgins CB, et al. Coronary sinus flow measurement by means of velocity-encoded cine MR imaging: validation by using flow probes in dogs. Radiology 2000;217:487-93.
33. Weiger M, Bornert P, Proska R, Schaffter T, Haase A. Motion-adapted gating based on k-space weighting for reduction of respiratory motion artifacts. Magn Reson Med 1997;38:322-33.
34. McConnell M, Khasgiwala V, Savord B, Chen M, Chuang M, Edelman R, et al. Prospective adaptive navigator correction for breath-hold MR coronary angiography. Magn Reson Med 1997;37:148-52.
35. Wang Y, Riederer S, Ehman R. Respiratory motion of the heart: kinematics and the implications for the spatial resolution of coronary imaging. Magn Reson Med 1995;33:713-19.
36. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1:307-10.
37. Campisi R, Nathan L, Pampaloni MH, Schoder H, Sayre JW, Chaudhuri G, et al.. Noninvasive assessment of coronary microcirculatory function in postmenopausal women and effects of short-term and long-term estrogen administration.Circulation 2002;105:425-30.
38. Bland D. Practical statistics for medical research. London: Chapman and Hall: 1991;455-60.
39. Angerer P, Kothny W, Stork S, von Schacky C. Hormone replacement therapy and distensibility of carotid arteries in postmenopausal women: a randomized, controlled trial. J Am Coll Cardiol 1789;36:1789-96.
40. Hodis HN, Mack WJ, Lobo RA, Shoupe D, Sevanian A, Mahrer PR, et al. Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Int Med 2001;135:939-53.
41. Hodis HN, Mack WJ, Azen SP, Lobo RA, Shoupe D, Mahrer PR, et al. Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. N Engl J Med 2003;349:535-45.
42. Vehkavaara S, Hakala-Ala-Pietila T, Virkamaki A, Bergholm R, Ehnholm C, Hovatta O, et al. Differential effects of oral and transdermal estrogen replacement therapy on endothelial function in postmenopausal women. Circulation 2000;102:2687-93.
43. Sorensen MB, Collins P, Ong PJL, Webb CM, Hayward CS, Asbury EA, et al. Long-term use of contraceptive depot medroxyprogesterone acetate in young women impairs arterial endothelial function assessed by cardiovascular magnetic resonance. Circulation 2002;106:1646-51.
44. Wong CM, Yao X, Au CL, Tsang SY, Fung KP, Laher I, et al. Raloxifene prevents endothelial dysfunction in aging ovariectomized female rats. Vasc Pharmacol 2006;44:290-8.
45. Barrett-Connor E, Grady D, Sashegyi A, Anderson PW, Cox DA, Hoszowski K, et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 2002;287:847-57.
46. Ensrud K, Genazzani AR, Geiger MJ, McNabb M, Dowsett SA, Cox DA, et al. Effect of raloxifene on cardiovascular adverse events in postmenopausal women with osteoporosis. Am J Cardiol 2006;97:520-7.
47. Gerhard M, Walsh BW, Tawakol A, Haley EA, Creager SJ, Seely EW, et al. Estradiol therapy combined with progesterone and endothelium-dependent vasodilation in postmenopausal women. Circulation 1158;98:1158-63.
48. Koh KK, Jin DK, Yang SH, Lee SK, Hwang HY, Kang MH, et al. Vascular effects of synthetic or natural progestagen combined with conjugated equine estrogen in healthy postmenopausal women. Circulation 2001;103:1961-6.
49. Herrington DM, Werbel BL, Riley WA, Pusser BE, Morgan TM. Individual and combined effects of estrogen/progestin therapy and lovastatin on lipids and flow-mediated vasodilation in postmenopausal women with coronary artery disease. J Am Coll Cardiol 1999;33:2030-7.
50. Sanada M, Higashi Y, Nakagawa K, Sasaki S, Kodama I, Tsuda M, et al. Relationship between the angiotensin-converting enzyme genotype and the forearm vasodilator response to estrogen replacement therapy in postmenopausal women. J Am Coll Cardiol 2001;37:1529-35.
51. McCrohon JA, Adams MR, McCredie RJ, Robinson J, Pike A, Abbey M, et al. Hormone replacement therapy is associated with improved arterial physiology in healthy post-menopausal women. Clinical Endocrinology 1996;45:435-41.
52. Lobo RA. Evaluation of cardiovascular event rates with hormone therapy in healthy, early postmenopausal women: results from 2 large clinical trials. Arch Int Med 2004;164:482-4.